Adaptimmune Therapeutics PLC (NASDAQ: ADAP) shares jumped on Friday after the company announced updated data from its early-stage clinical trial in patients with lung, head and neck cancers.
Specifically, the firm presented updated data from its ADP-A2M4 Phase 1 trial at the American Society for Clinical Oncology (ASCO) Annual Meeting.
The data demonstrated durability and responses in synovial sarcoma, supporting Spearhead-1 as a potential registrational trial. The ASCO presentation also described a new response in a patient with lung cancer, and a response in a patient with head and neck cancer (reported in January).
Separately, Adaptimmune announced new responses in the Surpass trial, confirming the potential for Spear T‑cell therapies targeting MAGE-A4 to treat a broad range of cancers in addition to sarcoma. These data further support the rationale for two new Phase 2 trials: Spearhead-2 in head and neck cancer, which will begin later this year, and a second trial in esophagogastric junction cancer planned for the first half of 2021.
Adrian Rawcliffe, CEO, commented:
I am pleased to announce that we have identified a new indication to progress into late stage development. We plan to initiate a Phase 2 trial in esophagogastric junction cancer in the first half of 2021, with our next-generation ADP-A2M4CD8 SPEAR T-cells. In addition, the ASCO data demonstrate promising durability for ADP-A2M4 in sarcoma bolstering our ambition to have our first marketed therapy in 2022. I’m thrilled with the responses in a broad range of tumors with our programs targeting MAGE-A4 and AFP. I am confident that we will be able to identify more indications for late stage development as more patients are treated in our trials.
Adaptimmune Therapeutics stock traded up about 72% on Friday, at $8.36 in a 52-week range of $0.71 to $10.19. The consensus price target is $4.40.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
